Company profile · Helsingborg, Sweden

Lead Biologics

Antibody Therapeutics, Biologics Discovery, Drug Development, and Biotech · Development-stage biologics platform

Lead Biologics runs biologics discovery, antibody program development, and therapeutics platform work in Helsingborg, Sweden.

Lead
Anki Malmborg Hager (verified ↗)
Address
Lead Biologics AB, Box 23163, SE-250 23 Helsingborg, Sweden (source ↗)
Compliance
Not yet on record
Last reviewed
22 Mar 2026 (2mo ago)
Scale
Development-stage biologics platform
Capabilities
Biologics Discovery · Antibody Program Development · Therapeutics Platform Work
Founded
2020
Headcount
1-10
Site and address
Clinical profileSTATUS: VERIFIED MARCH 2026

Anki Malmborg Hager

CEO

Check official leadership source
Full addressLead Biologics AB, Box 23163, SE-250 23 Helsingborg, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source

Official Lead Biologics contact page listing the Helsingborg address and CEO contact.

Open source
Operating profile

Development-stage biologics platform

Helsingborg, Sweden. Antibody Therapeutics, Biologics Discovery, Drug Development, and Biotech. Review completed on 22 Mar 2026.

2026 technical specializationAntibody Therapeutics, Biologics Discovery, Drug Development, and Biotech
Core capabilities
Biologics DiscoveryAntibody Program DevelopmentTherapeutics Platform Work
Governance

Swedish corporate and therapeutics-development oversight

Official leadership disclosure, Official Helsingborg address disclosure, Biologics platform claim

Editorial note

Antibody Therapeutics, Biologics Discovery, Drug Development, and Biotech

Lead Biologics is published because official company materials confirm current leadership, Helsingborg operating address, and a clear antibody-therapeutics platform.

Editorial note

Lead Biologics is published because official company materials confirm current leadership, Helsingborg operating address, and a clear antibody-therapeutics platform.

FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026Last reviewed: 22 March 2026
Capabilities

Core capabilities

Primary declared technical activities and areas of operating focus.

Biologics Discovery
Antibody Program Development
Therapeutics Platform Work
Verification source dossier

Verification source dossier

Official source set used to support leadership, physical-site, certification, and watch-note evidence.

Leadership evidenceOfficial Lead Biologics contact page naming Anki Malmborg Hager as CEO.Source origin: leadbiologics.comOpen source
Supporting evidenceOfficial Lead Biologics site describing the Helsingborg antibody-therapeutics platform.Source origin: leadbiologics.comOpen source
Physical-site evidenceOfficial Lead Biologics contact page listing the Helsingborg address and CEO contact.Source origin: leadbiologics.comOpen source
Infrastructure

Declared infrastructure

Biologics discovery workflow
Antibody development systems
Therapeutics program infrastructure
Regulatory posture

Quality system coverage

GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.

GMP
REVIEW IN PROGRESS 2026
GLP
REVIEW IN PROGRESS 2026
ISO-13485
REVIEW IN PROGRESS 2026
FDA-Inspected
REVIEW IN PROGRESS 2026
Verification history

Verification history

22 Mar 2026: Executive identity confirmed via official management disclosure.
22 Mar 2026: Full trust review completed.
FAQ

Frequently asked questions

Where is Lead Biologics located?
Lead Biologics operates from Lead Biologics AB, Box 23163, SE-250 23 Helsingborg, Sweden, Helsingborg, Sweden.
Who runs Lead Biologics?
Lead Biologics is led by Anki Malmborg Hager, CEO. Verified 22 Mar 2026.
What does Lead Biologics do?
Lead Biologics runs biologics discovery, antibody program development, and therapeutics platform work in Helsingborg, Sweden. Core capabilities: Biologics Discovery, Antibody Program Development, Therapeutics Platform Work.
Editorial context

Related technical briefs

Briefs that name Helsingborg as a covered market or city.